Category Archives: Doha Declaration

Why do new medicines cost so much, and what can we do about it?

  The cost of new drugs is putting increasing pressure on people in both rich and poor countries. We explain why it’s a burning issue by Sarah Boseley Health editor Why does it matter what medicines cost? If you are lucky enough … Continue reading

Posted in Doha Declaration, Patent, R&D, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

TRIPS Council Members: Defining IP Rights And The Public Interest

Source: IP Watch 15/06/2017 BY CATHERINE SAEZ, INTELLECTUAL PROPERTY WATCH “Political and economic pressure placed on governments to forgo the use of TRIPS flexibilities violates the integrity and legitimacy of the system of legal duties and rights created by the … Continue reading

Posted in Compulsory Licensing, Doha Declaration, HIV/Aids, TRIPS, US pressure on India | Leave a comment

It’s Official: TRIPS Health Amendment In Effect, First Ever To A WTO Agreement

Source: More than a decade after World Trade Organization member states approved the first-ever legal amendment to a WTO agreement, the change to the international intellectual property agreement has entered into effect. Five more members ratified the amendment in … Continue reading

Posted in Compulsory Licensing, Doha Declaration, TRIPS, TRIPS flexibilities, Uncategorized, WTO | Leave a comment

Access to affordable generic medicines for world’s poorest countries under threat

Source: MSF access; October 12, 2015 Geneva – Starting Thursday, 15 October, the Member States of the World Trade Organization will be considering a request by the world’s poorest countries to be  exempted from implementing medicine patents for as long as … Continue reading

Posted in August 30 decision, Compulsory Licensing, Doha Declaration, Generics, LDC transition period, LDCs, WTO | Leave a comment

TPP draft reveals surgical strike on public health

Source: East Asia Forum On 13 November, WikiLeaks released a secret draft text of the Intellectual Property Chapter of the Trans-Pacific Partnership (TPP). The text reveals substantive proposals for expanded protection in respect of copyright, patent, trade mark andtrade secrets law, and intellectual property enforcement. Across this, there … Continue reading

Posted in Compulsory Licensing, Doha Declaration, Generics, IP Rights, Patents, Right to Health, TPP, TPP, TRIPS, TRIPS plus, USTR 301 report, WHO, WTO | Leave a comment

The Op-Ed: What Patent Reform In Brazil And South Africa Can Mean

Source: Pharmalot In recent months, two countries with large economies and large populations both took steps to rework their patent laws, in part, to expand access to medicines. The moves come amid increasing concerns that treatments for certain ailments, such … Continue reading

Posted in Brazil Patent Reform, Doha Declaration, Draft South Africa Policy on IP 2013, Generics, HIV/Aids, IP Rights, IPR Enforcement, Patents, Right to Health, TRIPS, TRIPS flexibilities, Voluntary License, WTO | Tagged | Leave a comment

What Does WTO Extension For LDCs To Enforce IP Mean For Pharmaceuticals?

Source: Ip-Watch The recent extension granted by World Trade Organization members to least developed countries giving 8 more years to implement international intellectual property protection rules threw a shroud of confusion over a parallel WTO waiver for pharmaceutical products conferred … Continue reading

Posted in Compulsory Licensing, Doha Declaration, IP Rights, LDCs, TRIPS, WTO | Tagged , | Leave a comment